{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 91 of 92', 'CR845-CLIN3103', '14.6', 'Statistical Appendix', 'This appendix provides further details related to the treatment of missing data for the', 'primary and sensitivity analyses of the primary endpoint.', 'For multiple imputations and other instances where random seeds are required, the values', 'used (in order) are:', '8392857', '2985729', '1843255', '9086284', '5547484', '8017456', '9597295', '2252256', '4821871', '9852467', '5126715', '3232132', '9841654', '3645284', '1587345', 'Note that not all seeds may be required in programming the multiple imputations. If', 'additional seeds are needed, they will be chosen by adding 1 to each of the values above,', 'again using them in order.', 'The number of imputations for the multiple imputations will be 20.', 'For the primary analysis, a multi-stage process will be applied:', 'Stage 1: Subjects will have their 11-point NRS scores imputed. First, using all visits,', 'intermittent missing data will be imputed using the Markov Chain Monte Carlo (MCMC)', 'method implemented with the SAS MI procedure; data imputed following subject', 'discontinuation via this process will be censored out of the resulting dataset so that only', 'intermittent missing data is imputed via this method. Second, monotone missing data', 'will be imputed following subject discontinuation using SAS proc MI. For each stage,', 'MI will be performed within treatment group with covariates for baseline NRS score, use', 'of prior anti-itch medication, and presence of select medical conditions. Should', 'convergence issues occur due to small cell size for the one or both of the categorical', 'covariates at either stage, the appropriate covariate(s) will be removed from the model.', 'Stage 2: Using the resulting complete datasets, the change from baseline with respect to', 'the 11-point NRS will be calculated; patients will be categorized as responder if they', 'have a 3-point (or greater) improvement over baseline. Week 12 values will serve as the', 'primary timepoint. The 20 MI runs will be analyzed independently using a logistic', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 92 of 92', 'CR845-CLIN3103', 'model and the results combined using SAS proc MIANALYZE. Logistic model', 'covariates will include treatment, baseline NRS score, use of prior anti-itch medication,', 'and presence of select medical conditions. As with the MI, should convergence issues', 'occur due to small cell sizes, the appropriate categorical covariate(s) will be dropped as', 'necessary.', 'Should a sample size increase occur, the above process will be implemented completely', 'independently among subjects contributing the interim results and those following the', 'interim analysis.', 'For the tipping point analysis, a shift parameter will be applied to only subjects in the', 'active group, running from 0 to 5 points in 0.25-point increments or until the conclusions', 'of the analysis \"tip\" and the results are no longer significant. This analysis will not be', 'performed should the initial primary results fail to achieve significance.', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}